Human Serum Albumin-Based Nanoparticles for Targeted Intracellular Drug Delivery
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26178297 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Claudia Gabriela Chilom und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Physics, University of Bucharest Magurele, 077125 Magurele, Ilfov, Romania. Hauptthemen laut MEDLINE: Nanoparticles, Serum Albumin, Human, Drug Delivery Systems, Drug Carriers. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Unitatea Executivă pentru Finanțarea Învățământului Superior, a Cercetării, Dezvoltării și Inovării, UEFISCDI Project, New hybrid protein nanostructures for targeting specific in colon tumor cells (Prot-Col-Target).
Abstract (Originalsprache)
We report the synthesis and characterization of folic acid (FA)-conjugated human serum albumin nanoparticles, (HSA-FA):Ru NPs, as targeted carriers for rutin (Ru), a flavonoid with known anticancer activity. Nanoparticles were fabricated via a desolvation method, and their surface was functionalized with folic acid to promote selective uptake by cancer cells overexpressing folate receptors. Morphological and dimensional analyses performed by atomic force microscopy (AFM), scanning electron microscopy (SEM), and fluorescence microscopy confirmed that all nanoparticles were below 100 nm and exhibited good colloidal stability. Voltametric measurements confirmed the successful incorporation of both rutin and folic acid within the (HSA-FA):Ru nanoparticle formulation. Biological evaluation was conducted on healthy L929 fibroblasts and HT-29 colon adenocarcinoma cells. MTS colorimetric assays revealed that (HSA-FA):Ru NPs significantly reduced the viability of HT-29 cells, while maintaining higher compatibility with L929 cells. Fluorescence and electron microscopy further confirmed preferential nanoparticle uptake and surface accumulation in HT-29 cells, supporting the role of folic acid in enhancing targeted delivery. The study demonstrates that HSA-based nanoparticles functionalized with FA and loaded with Ru offer a biocompatible and efficient strategy for selective intracellular drug delivery in colorectal cancer. These findings support the use of albumin-based nanocarriers in the development of targeted therapeutic platforms for cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Physics, University of Bucharest Magurele, 077125 Magurele, Ilfov, Romania.
- National Institute of Materials Physics, Str. Atomistilor, nr. 405A, 077125 Magurele, Ilfov, Romania.
ORCID-Profile: Claudia Gabriela Chilom, Sorina Iftimie, Daniela Oprea, Monica Enculescu, Teodor Adrian Enache
Förderung
- Unitatea Executivă pentru Finanțarea Învățământului Superior, a Cercetării, Dezvoltării și Inovării
- UEFISCDI Project
- New hybrid protein nanostructures for targeting specific in colon tumor cells (Prot-Col-Target)
Zitieren
APA
Chilom, C. G., Iftimie, S., Balan, A. E., Oprea, D., Enculescu, M., & Enache, T. A. (2025). Human Serum Albumin-Based Nanoparticles for Targeted Intracellular Drug Delivery. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178297
Vancouver
Chilom CG, Iftimie S, Balan AE, Oprea D, Enculescu M, Enache TA. Human Serum Albumin-Based Nanoparticles for Targeted Intracellular Drug Delivery. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26178297
BibTeX
@article{Chilom2025,
author = {Chilom, Claudia Gabriela and Iftimie, Sorina and Balan, Adriana Elena and Oprea, Daniela and Enculescu, Monica and Enache, Teodor Adrian},
title = {Human Serum Albumin-Based Nanoparticles for Targeted Intracellular Drug Delivery},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26178297}
}
EUVIMED